Latham Advises Invetx in its US$60.5 Million Series B Financing

A Boston-based team advises on the oversubscribed funding round.

May 10, 2022

Invetx, a pioneer in protein-based therapeutics for animal health, has announced that it has raised US$60.5 million in an oversubscribed Series B financing. The investment was led by F-Prime Capital, Novo Holdings, GV (formerly Google Ventures) and Eight Roads, with participation from existing investors Anterra Capital, Casdin Capital and funds managed by Tekla Capital Management, LLC. The proceeds allow the company to advance its monoclonal antibody (mAb) pipeline and pursue market approvals for therapeutics targeting chronic and serious diseases in dogs and cats.

Latham & Watkins advised Invetx on its financing round with a corporate deal team led by Boston partners Spencer Ricks and Kristen Grannis, with associates Peter Prial and Andrew Rondeau.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.